Consensus NeuroSense Therapeutics Ltd.

Equities

NRSN

IL0011809592

Market Closed - Nasdaq Other stock markets 01:30:00 09/05/2024 am IST			5-day change	1st Jan Change
1.23 ^USD	-4.65%		-8.89%	+56.69%

07/05	NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients	CI
22/04	NeuroSense to Collaborate With Genetika+ on Alzheimer's Disease Drug Development; Shares Fall	MT

Evolution of the average Target Price on NeuroSense Therapeutics Ltd.

Price target over the last 5 years

History of analyst recommendation changes

9c1734849639f0d249aa68.9QnEx8-NXB0yqdNcdXrHFFL2oOZA0n6hh5upwQeoSk4.kGqcl4rUP1Jbnak2BQCFfmfG-oR0kD2Xyf3dgErmIjinfYOOqd4MUmLGsA~f8805286d4673cf67950ee9d18215a04

Analyst Recommendations on NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Prices $4.5 Million Offering of Ordinary Shares, Warrants	11/04	MT
Alliance Global Partners Initiates NeuroSense Therapeutics at Buy Rating With $7.50 Price Target	17/23/17	MT
Maxim Starts NeuroSense Therapeutics at Buy with $7 Price Target	08/22/08	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.29 USD

Average target price

5.25 USD

Spread / Average Target

+306.98%

High Price Target

7.5 USD

Spread / Highest target

+481.40%

Low Price Target

3 USD

Spread / Lowest Target

+132.56%

Consensus detail

Consensus revision (last 18 months)

Analysts covering NeuroSense Therapeutics Ltd.

Alliance Global Partners
Maxim

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar